LILRB4
Leukocyte immunoglobulin-like receptor subfamily B member 4
Also known as: CD85k, HM18, ILT3, LIR-5, LIR5, LIRB4_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8NHJ6
- Gene
- LILRB4
- Ensembl
- ENSG00000186818
- Chromosome
- 19
- Canonical length
- 448 aa
- Protein class
- CD markers, Predicted intracellular proteins, Predicted membrane proteins
OverviewNCBI Gene
This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. The receptor can also function in antigen capture and presentation. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
448 residues, UniProt reviewed canonical sequence.
>Q8NHJ6|LILRB4
1 MIPTFTALLC LGLSLGPRTH MQAGPLPKPT LWAEPGSVIS WGNSVTIWCQ GTLEAREYRL
61 DKEESPAPWD RQNPLEPKNK ARFSIPSMTE DYAGRYRCYY RSPVGWSQPS DPLELVMTGA
121 YSKPTLSALP SPLVTSGKSV TLLCQSRSPM DTFLLIKERA AHPLLHLRSE HGAQQHQAEF
181 PMSPVTSVHG GTYRCFSSHG FSHYLLSHPS DPLELIVSGS LEDPRPSPTR SVSTAAGPED
241 QPLMPTGSVP HSGLRRHWEV LIGVLVVSIL LLSLLLFLLL QHWRQGKHRT LAQRQADFQR
301 PPGAAEPEPK DGGLQRRSSP AADVQGENFC AAVKNTQPED GVEMDTRQSP HDEDPQAVTY
361 AKVKHSRPRR EMASPPSPLS GEFLDTKDRQ AEEDRQMDTE AAASEAPQDV TYAQLHSFTL
421 RQKATEPPPS QEGASPAEPS VYATLAIHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LILRB4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.52
- Highest tissue expression
- 18 nTPM
Expression across tissuesHPA
Tissue
- spleen: 18 nTPM
- spinal cord: 14 nTPM
- lung: 13 nTPM
- lymph node: 11 nTPM
- appendix: 11 nTPM
- blood vessel: 11 nTPM
Single-cell type
- microglia: 139 nCPM
- kupffer cells: 10 nCPM
- monocytes: 9.1 nCPM
- macrophages: 8.6 nCPM
- pdcs: 7.6 nCPM
- monocyte progenitors: 5.5 nCPM
Immune cell
- plasmacytoid DC: 38 nTPM
- myeloid DC: 12 nTPM
- intermediate monocyte: 11 nTPM
- non-classical monocyte: 9 nTPM
- classical monocyte: 7.9 nTPM
- total PBMC: 3.8 nTPM
Brain region
- medulla oblongata: 3.6 nTPM
- pons: 3 nTPM
- white matter: 3 nTPM
- midbrain: 2.8 nTPM
- spinal cord: 2.8 nTPM
- thalamus: 2.4 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.34
- gnomAD pLI
- 0
- gnomAD missense Z
- -1.43
- DepMap mean gene effect
- 0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adaptive immune response
- cytokine-mediated signaling pathway
- Fc receptor mediated inhibitory signaling pathway
- immune response-regulating signaling pathway
- interleukin-10-mediated signaling pathway
- negative regulation of activated T cell proliferation
- negative regulation of canonical NF-kappaB signal transduction
- negative regulation of chemokine production
- negative regulation of cytokine production involved in inflammatory response
- negative regulation of interleukin-1 beta production
- negative regulation of interleukin-10 production
- negative regulation of interleukin-2 production
- negative regulation of interleukin-5 production
- negative regulation of interleukin-6 production
- negative regulation of intracellular signal transduction
- negative regulation of IP-10 production
- negative regulation of MAPK cascade
- negative regulation of miRNA transcription
- negative regulation of monocyte activation
- negative regulation of osteoclast differentiation
- negative regulation of protein localization to nucleus
- negative regulation of T cell costimulation
- negative regulation of T cell cytokine production
- negative regulation of T cell proliferation
- negative regulation of T cell receptor signaling pathway
- negative regulation of tumor necrosis factor production
- negative regulation of type II interferon production
- positive regulation of CD8-positive, alpha-beta T cell differentiation
- positive regulation of regulatory T cell differentiation
- positive regulation of T cell anergy
- receptor internalization
- tolerance induction
- negative regulation of cytotoxic T cell differentiation
Molecular functions
- apolipoprotein binding
- fibronectin binding
- inhibitory MHC class I receptor activity
- protein phosphatase binding
- protein tyrosine kinase inhibitor activity
- signaling receptor inhibitor activity
- transmembrane receptor protein tyrosine kinase inhibitor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LILRB4 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LILRB4 as an antibody target. Whether an autoantibody or antibody against LILRB4 could matter depends on whether native LILRB4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LILRB4 is annotated at the cell surface, where native LILRB4 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LILRB4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...